VEGFR3
6 drugs OncologyRespiratory
5
approved indications
6
Approved Drugs
6
Companies
22
Indications
2
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (6 companies)
✓ All 6 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (22 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
EISAI INC 1 drug
Eli Lilly 1 drug
CPPI CV 1 drug
By Therapeutic Area
Other 3 drugs
Oncology 2 drugs
By Therapeutic Area
Other 3 drugs
LENVIMA, SUTENT, STIVARGA
Oncology 2 drugs
RETEVMO, SUNITINIB MALATE
Respiratory 1 drugs
OFEV
Indications Treated
Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancerAdvanced renal cell carcinoma (first-line, in combination with pembrolizumab)Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus)Unresectable hepatocellular carcinoma (first-line)Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab)Gastrointestinal Stromal TumorRenal Cell CarcinomaPancreatic Neuroendocrine TumorNon-Small Cell Lung CancerMedullary Thyroid CancerThyroid CancerSolid TumorsGastrointestinal stromal tumor (GIST)Advanced renal cell carcinoma (RCC)Adjuvant treatment of renal cell carcinoma (RCC) at high risk of recurrence following nephrectomyProgressive, well-differentiated pancreatic neuroendocrine tumors (pNET)Metastatic colorectal cancerLocally advanced, unresectable or metastatic gastrointestinal stromal tumorHepatocellular carcinomaIdiopathic Pulmonary FibrosisInterstitial Lung DiseaseSystemic Sclerosis-Associated Interstitial Lung Disease